1. Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation
- Author
-
Diana Dudziak, Christin Brückner, Falk Nimmerjahn, and Christian H. K. Lehmann
- Subjects
0301 basic medicine ,Immunology ,Receptors, Cell Surface ,Inflammation ,medicine.disease_cause ,Immunoglobulin G ,Autoimmune Diseases ,Autoimmunity ,03 medical and health sciences ,Immune system ,C-type lectin ,Animals ,Humans ,Immunology and Allergy ,Medicine ,Lectins, C-Type ,biology ,Cell adhesion molecule ,business.industry ,Mechanism (biology) ,Immunoglobulins, Intravenous ,General Medicine ,030104 developmental biology ,biology.protein ,Antibody ,medicine.symptom ,business ,Cell Adhesion Molecules - Abstract
A hallmark of many chronic inflammatory and autoimmune diseases is that there is an impaired resolution of inflammation and return to the steady state. The infusion of high doses of pooled serum IgG preparations from thousands of donors [intravenous immunoglobulin (IVIG) therapy] has been shown to induce resolution of inflammation in a variety of chronic inflammatory and autoimmune diseases, suggesting that IgG molecules can instruct the immune system to stop inflammatory processes and initiate the return to the steady state. The aim of this review is to discuss how insights into the mechanism of IVIG activity may help to understand the molecular and cellular pathways underlying resolution of inflammation. We will put a special emphasis on pathways dependent on the IgG FC domain and IgG sialylation, as several recent studies have provided new insights into how this glycosylation-dependent pathway modulates innate and adaptive immune responses through different sets of C-type or I-type lectins.
- Published
- 2017
- Full Text
- View/download PDF